Trial Profile
A Phase III, Observer-blinded Randomised, Multi-centre Clinical Study of the Safety, Immunogenicity and Consistency of Three Manufacturing Lots of GSK Biologicals' Candidate Tdap Vaccine as Compared to a US-licensed Td Vaccine When Given as a Booster Dose to Healthy Adolescents (10-18 Years of Age)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs DTaP vaccine (Primary) ; Diphtheria-tetanus vaccine
- Indications Diphtheria; Pertussis; Tetanus
- Focus Pharmacodynamics
- Sponsors GSK
- 05 Nov 2010 New trial record.